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Monika Engels3, Marco Franchini3, Regina Hofmann-Lehmann1 and Hans Lutz1
Abstract
Domestic cats are commonly affected by viral pathogens that induce lengthy infections with fatal outcomes.
Prevention of viral propagation is of primordial importance in shelters and catteries, where cats from different
backgrounds have narrow contacts. Oligonucleotides (ODN) containing cytosine-phosphate-guanosine motifs of
class A (CpG-A) are highly potent synthetic inducers of innate antiviral mechanisms. The aim of this study was to
test their ability to modulate innate immune responses and prevent viral replication as stand-alone agents in the
domestic cat. CpG-A stimulation of feline peripheral blood mononuclear cells (PBMCs) enhanced their proliferation,
increased the presence of co-stimulatory molecules on their surface and influenced their gene expression profiles in
an antiviral orientation. Incubation of the supernatants of CpG-A stimulated PBMCs with feline cell lines of epithelial
and fibroblastic origin induced expression of the antiviral myxovirus resistance (Mx) gene in these target cells,
which also showed enhanced resistance to feline viruses from five distinct families, namely Coronaviridae,
Herpesviridae, Caliciviridae, Parvoviridae, and Retroviridae. Most importantly, subcutaneous administration of CpG-A in
domestic cats systemically increased the expression of Mx, reaching maximal levels within 24 h. Plasma from
treated cats could furthermore inhibit viral replication in vitro. Altogether, our data highlight the promising potential
of CpG-A to induce a preventive antiviral state in the cat and to protect feline populations against a broad range of
virus infections.
Introduction
Feline viruses are of particularly opportunistic character.
In order to adapt to the solitary way of life of ancestral
felids, these pathogens have acquired elaborate means to
persist within their host population over the course of
time. The infection of new hosts upon the rare contact
between individuals was evolutionarily assured by very
efficient transmission strategies and the induction of la-
tent, chronic and/or asymptomatic infections. Often
kept in multi-cat households and placed in catteries or
shelters, today’s domestic cat is consequently particularly
susceptible to viral infections [1,2]. The close proximity
and high social contact rate of animals with different
vaccination states in these stressful environments further
increases the risk of infection. Moreover, the strong anti-
genic variability of several common feline viruses includ-
ing the feline calicivirus (FCV), the feline coronavirus
(FCoV) and the feline leukemia virus (FeLV) support es-
cape from immune responses and lower the efficacy of
currently available vaccines [3]. The availability of com-
plementary prophylactic strategies could help protect
pet cats in environments with high infectious pressure
from long diseases and/or death caused by infections
with fatal viruses.
A promising addition to vaccination is the manipula-
tion of innate immunity. Innate pathogen recognition re-
lies on a set of sensory molecules, the Toll-like receptors
(TLRs), which enable the immediate reaction of specific
immune cells to pathogen “danger signals”, the so-called
pathogen-associated molecular patterns (PAMPs) [4].
Due to their abundance in all bacterial as well as some
viral genomes, oligodeoxynucleotides (ODN) containing
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unmethylated cytosine–phosphate–guanosine (CpG)
motifs are effectively recognized as PAMPs by the ver-
tebrate innate immune system [5]. Response to CpG
ODN stimulation is conferred through TLR9, expressed
mainly in the intracellular compartments of human B
cells and plasmacytoid dendritic cells (pDCs) [6,7].
Alarmed TLR9 is the initial instigator of gene expres-
sion profiles that strongly support antiviral mechan-
isms: upregulation of costimulatory molecules major
histocompatibility complex (MHC) II, B7.1 and B7.2
on the surface of stimulated cells provides them with a
stronger antigen presenting potential [8,9] and produc-
tion of cytokines such as type I interferon (IFN), inter-
leukin (IL)-12, IFNγ, IL-6 and tumor necrosis factor
(TNF)α, contribute to providing an optimal immune
environment for the development of innate and adap-
tive responses against intracellular pathogens [10,11].
Probably the most important antiviral property of CpG
ODN resides in their potential to stimulate the pro-
duction of high amounts of type I IFN by pDCs [12].
This family of cytokines, which includes IFNα, IFNω
and IFNβ, has been shown to considerably enhance
natural killer (NK) cell cytotoxicity [13], promote dif-
ferentiation, maturation and immunostimulatory func-
tions of monocytes and DCs [14], induce B cell
production of immunoglobulin [15] and T-helper (Th)
1 differentiation of T cells [16,17]. Moreover, upon
binding to their ubiquitously distributed receptor, type
I IFNs effectively induce the synthesis of various intra-
cellular proteins which interfere with the replication
of a broad range of viruses [18]. The myxovirus-
resistance protein (Mx) GTPase is a well-studied ex-
ample of these intracellular antiviral effectors. This
enzyme is known to be directly regulated by the type
I IFN, and its detection is readily used as marker for
upregulation and biological activity of this cytokine
family [19].
Distinct classes of ODN have been shown to induce
differential immune responses [20]. Class A CpG ODN
(CpG-A) consist of CpG motifs in a phosphodiester
core, flanked on both ends by phosphorothioate poly (G)
sequences. CpG ODN of this class are characterized by
their potential to both induce massive type I IFN secre-
tion by pDCs [12] and increase NK cytotoxicity [21],
rendering them ideal candidates as prophylactic enhan-
cers of innate immunity to viral infections. Conversely,
class B CpG ODN (CpG-B), which encode multiple CpG
motifs on a phosphorothioate backbone, promote mono-
cyte maturation and B cell activation, thus substantially
supporting the development of humoral immune
responses [22-24]. Both CpG-A and CpG-B have
indicated immunostimulatory properties in immune
cells of mice, primates and many domestic species
in vitro [25-31], while in vivo studies in outbred
animals have mainly been carried out with CpG-B
[24,32,33]. Concerning the cat, specifically synthesized
CpG-A molecules were recently shown to induce IFNγ
[34]; CpG-B molecules indicated the capability to induce
proliferation of feline cells [35], and CpG-B-adjuvanted
allergen indicated potential for immunotherapy in a fe-
line asthma model [36]. Although class C [37,38] and
class P ODN [39] were developed in more recent years
in an effort to combine the advantageous effects of both
CpG-A and CpG-B and increase immunogenicity, CpG-
A remain the strongest inducers of type I IFN described
to date.
The potential of CpG ODN as prophylactic stand-
alone inducers of innate defense mechanisms has been
the subject of only few studies. Most works in this field
initially described protection of mice against bacterial
[40-44] and parasitic [45-47] infections. More recently,
induction of resistance to viral infections was shown also
in mouse models for Herpes Simplex Virus [48], neuro-
tropic arenavirus [49], foot and mouth disease virus [50]
and Vaccinia virus [51]. With exception of the latter, all
these studies were carried out with CpG-B. In an out-
bred species, partial antiviral protection has only been
described in two studies so far, in which reduced shed-
ding of herpes and parainfluenza viruses was observed
in lambs after administration also of a CpG-B [52,53].
To our knowledge, prophylactic antiviral potential of
CpG-A has not yet been described in outbred animals.
We carried out a series of experiments with the ob-
jective to characterize both the immunomodulatory and
antiviral properties of CpG-A in the domestic cat. In
vitro, the prototype of CpG-A, ODN 2216 [12], strength-
ened the antiviral qualities of feline immune cells and
stimulated their production of soluble molecules that
inhibited the replication of five different families of
viruses: Coronaviridae, Herpesviridae, Caliciviridae,
Parvoviridae, and Retroviridae. In vivo, ODN 2216
induced a systemic antiviral state.
Materials and methods
Animals and ethics statement
Fourteen male castrated SPF cats divided in four differ-
ent age groups were used in this study: group 1 (c01-
c04, 10 weeks), group 2 (c05-c08, 1.5 years), group 3
(c09-c12, 7 years) and group 4 (c13 and c14, 14 years).
Cats c13 and c14 from group 4 originated from the same
litter; all other individuals were not related to each
other. The in vivo experiments were conducted when
cats c05-c08 were 3 years of age. All animals were pur-
chased from Liberty Research Inc. (Waverly, NY, USA)
and their SPF status was verified as previously described
[54]. This study was carried out in strict accordance with
regulations of the Swiss law for animal protection (SR
445.1). The Veterinary Office of the Swiss Canton of
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Zurich officially revised the protocol and approved the
study (Permit no. TVB 99/2007 and TVB 100/2007).
The animals were housed in groups in an animal-
friendly barrier facility under optimal ethological condi-
tions [55]. For blood collections and injections, the cats
were sedated with a combination of ketamin and mida-
zolam, and all possible efforts were made to minimize
stress and suffering.
Feline PBMC isolation, cell lines, ODNs, cell culture and
cell viability assay
Feline PBMCs were isolated from EDTA-anticoagulated
whole blood by Ficoll-Hypaque density gradient centri-
fugation using a standard protocol [56]. Purified cells
were counted prior to their utilization in the different
experiments using the Sysmex XT 2000iV (Sysmex,
Norderstedt, Germany) as described previously [57], and
cultured in RPMI 1640 with Glutamax I (Gibco®, Invi-
trogen, Basel, Switzerland). Adherent CRFK (ATCC no.
CCL-94) and FEA cells were maintained in RPMI 1640
with Glutamax I, while adherent fcwf-4 cells (ATCC no.
CRL-2787) were cultured in EMEM (ATCC 30–2003).
All media were supplemented with 10% heat-inactivated
fetal calf serum (Bioconcept, Allschwil, Switzerland), 100
U/mL penicillin and 100 mg/mL streptomycin (Gibco®,
Invitrogen).
ODN 2216 and ODN 2243 were obtained from Alexis
biochemicals, Enzo Life Sciences AG, Switzerland for
in vitro studies and ODN 2216 was synthesized by
Microsynth AG, Balgach, Switzerland for the in vivo ex-
periment. Recombinant feline IFNα (rfeIFNα) was
obtained from PBL Biomedical, Piscataway, New Jersey,
USA. All molecules were solubilized in endotoxin-free
PBS. ODN 2243 consists of the same sequence as ODN
2216, with CpG motifs inversed to GpC. For in vitro
experiments, both ODNs and rfeIFNα were diluted in
RPMI 1640 with Glutamax I supplemented as described
above.
Viability of stimulated cells was compared using the
trypan blue exclusion test. Briefly, after stimulation for
24 h with increasing concentrations of ODN 2216, ODN
2243 or equivalent volumes of PBS as control, cells were
stained with a 0.4% trypan blue solution (Dr Bender and
Dr Hobein AG, Zurich, Switzerland) and percentages of
viable cells were compared.
Proliferation assay
PBMCs were seeded immediately after isolation at a
concentration of 3 × 106 cells/mL in 96-well U-bottom
plates. Triplicate cultures for each cat were treated with
either 4 μg/mL ODN 2216 or 2243 or an equal volume
of endotoxin-free PBS. After an initial incubation of
18 h, the cells were pulsed for 24 h with 3H-thymidine
(Perkin Elmer, Schwerzenbach, Switzerland). Standard
liquid scintillation protocols were used for harvesting of
the cells and uptake of 3H was assessed with the Pack-
ard Tri-Carb 1600TR liquid scintillation analyzer (Perkin
Elmer). Proliferation rates were calculated as the mean
counts per minute (c.p.m) of triplicate cultures. The
stimulation index (SI) depicted in Figure 1 was calcu-
lated as follows:
Mean c:p:m:of ODN treated cultures
Mean c:p:m of PBS treated cultures
Flow cytometry
PBMCs were treated at a density of 3 × 106 cells/mL with
4 μg/mL ODN 2216 or ODN 2243 or an equivalent vol-
ume of endotoxin-free PBS and cultured for 24 h in a
12-well format. During collection of the cells, the adher-
ent cell fraction was removed with 0.05% trypsin-EDTA
(Gibco®, Invitrogen). Harvested cells were divided into 3
fractions labeled separately with either anti-feline B7.1
mouse monoclonal IgG (kindly provided by Prof Mary
Tompkins, Flow Cytometry and Cell Sorting Laboratory,
NC State College of Veterinary Medicine, USA), anti-fe-
line MHCII mouse monoclonal IgG1 (Department of
Pathology, Microbiology and Immunology, University of
California, Davis, USA) or fluoresceinisothiocyanate
(FITC)-conjugated mouse IgG1 as isotype control (BD
Bioscience, Allschwil, Swizerland). The fractions were
subsequently stained with R-Phycoerythrin (RPE)-conju-
gated goat anti-mouse IgG1 (BioConcept, Allschwil, Swi-
zerland). Fluorescence data was obtained using the
FACSCalibur® instrument (Becton Dickinson, Allschwil,
Switzerland) and the CellQuestPro™ software. Gates
representing lymphocyte and non-lymphocyte popula-
tions were set on the basis of forward versus side scatter,
and a total of 50 000 events were acquired in the non-
lymphocyte gate. Data was analyzed with the FlowJo
software (Tree Star, Olten, Switzerland), whereby an
additional gate was set comprising both lymphocyte and
non-lymphocyte populations (PBMC gate). MHCII and
B7.1 expression levels were determined as mean of fluor-
escence intensity for each gated cell population. Identical
gates were set for all cats in such a way that they com-
prise the desired cell populations of each animal.
Relative gene expression analysis
PBMCs were stimulated with ODN 2216, ODN 2243 or
endotoxin-free PBS at a density of 3 × 106 cells/mL dir-
ectly after isolation, while CrFK, FEA or fcwf-4 cells
were cultured to confluency prior to stimulation. Experi-
ments were carried out in a 96-well format. For stimula-
tion of adherent cells with supernatants (production see
below), total cell culture medium was discarded from
the wells and the monolayers were further cultured in
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100 μL undiluted supernatants for the rest of the experi-
ment. At time points relevant to each experiment, the
supernatants were removed and cells were lysed with
mRNA lysis buffer (mRNA isolation kit I, Roche Diag-
nostics, Rotkreuz, Switzerland). mRNA extractions were
performed with the mRNA Isolation Kit I and MagNA
Pure LC Instrument (Roche Diagnostics) and first strand
cDNA was synthesized with the High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems, Rotkreuz,
Switzerland). Real-time quantitative PCR (qPCR) reac-
tions consisted of 5 μL cDNA in a total volume of 25 μL
per reaction using the TaqMan® Fast Universal PCR
Master Mix (Applied Biosystems). Thermocycling condi-
tions included an initial denaturation of 20 s at 95°C fol-
lowed by 45 cycles of amplification by melting at 95°C
for 3 s and annealing at 60°C for 45 s. Primers and probes
Figure 1 ODN 2216 induce proliferation of primary feline immune cells and enhance their expression of costimulatory surface
molecules. (A) The proliferation of feline PBMCs of eight adult cats belonging to groups 2 and 3 after stimulation with ODN 2216 and ODN 2243
was assessed by H3-thymidine incorporation. The dots indicate the stimulation index calculated from triplicate cultures for each cat. (B and C)
Expression levels of B7.1 and MHCII surface molecules were assessed 24 h post stimulation with the indicated treatments by flow cytometry. The
fluorescence of gated PBMCs of one cat selected as an example is depicted. Isotype control samples are indicated as unstained. (D-G) Mean
fluorescence intensity (MFI) for B7.1 (D and E) and MHCII (F and G) of gated lymphocytes and non-lymphocyte subpopulations stimulated with
the indicated treatments. Results for eight cats belonging to groups 2 and 3 are shown. *p< 0.05, **p< 0.01.
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for feline genes have been previously described [58].
mRNA expression factors of selected genes, which cor-
respond to ratios of mRNA levels measured in ODN
2216 or ODN 2243 stimulated versus PBS stimulated
cells, were calculated and normalized with GeNorm ver-
sion 3.5 [59], using either both feline β-glucuronidase
(GUSB) and tryptophan 5-monooxygenase activation
protein zeta polypeptide (YWHAZ) (usually) or Glyceral-
dehyde 3-phosphate dehydrogenase (GAPDH) alone
(when specified) as reference genes, under conditions
validated for the feline species [60]. Generally depicted in
the graphs are mean expression factors calculated from
duplicate experiments carried out simultaneously. Where
results of one cat are illustrated, experiments were con-
ducted with cells of at least 3 individual animals and rep-
resentative data is shown.
Production of supernatants
For each cat, PBMCs were resuspended in supplemented
RPMI 1640 with Glutamax I (Gibco®, Invitrogen) at a
concentration of 106 cells/mL in 6-well plates and stimu-
lated immediately after isolation with 4 μg/mL ODN
2216, 4 μg/mL ODN 2243 or an equivalent volume of
endotoxin-free PBS. After 24 h incubation, supernatants
were harvested by centrifugation of the cultures twice at
2000 × g for 10 min, aliquoted and stored at −20°C.
Large supernatant quantities were produced with
PBMCs purified after one blood collection, enabling the
utilization of the same supernatants for virus inhibition
experiments concerning VSV, FCV, FCoV, FHV and
FPV. New supernatant batches were produced for use in
FeLV inhibition assays. Supernatants derived from
PBMCs stimulated with ODN 2216, ODN 2243 and
endotoxin-free PBS are referred to as Sup2216, Sup
2243 and Sup Neg in the text and in the figures.
Western blot
CrFK and fcwf-4 grown to confluency in 12-well plates
were stimulated with 600 μL of PBMC supernatants pro-
duced as explained above. At the time points indicated,
cells were harvested and counted. 106 cells of either cell
line were resuspended in 30 μL sample buffer (0.5 M
Tris(hydroxymethyl)aminomethane, 5% SDS, 10% β-
mercaptoethanol, 40% glycerol, and 0.05% bromphenol
blue) and boiled at 95°C for 5 min. SDS-PAGE separ-
ation and submersed immunoblotting procedures were
carried out as previously described [61]. The Spectra
Multicolor Broad Range Protein Ladder (Fermentas
GmbH, St. Leon-Rot, Germany) served as molecular
weight standard marker for each blot. For protein
visualization, membranes were first cut immediately
below the 80kB marker band. The top and bottom mem-
brane fractions were incubated with murine anti-human
Mx MAb M143 (generously provided by Dr J. Pavlovic,
Institute for Virology, University of Zürich, Switzerland)
and murine anti-β-actin monoclonal antibody as a load-
ing control (Sigma Aldrich GMbH, Buchs, Switzerland)
respectively. Both fractions were subsequently incubated
with a peroxidase-labelled goat anti-mouse IgG (Jackson
Immunoresearch, Newmarket, Suffolk, UK). Bands were
digitalized using the Chemigenius 2 BioImaging System
(Syngene, Cambridge, UK).
Viruses and viral inhibition assays
VSV Indiana strain (Institute of Virology, Vetsuisse Fac-
ulty, University of Zurich, Switzerland), FCoV Wellcome
strain (a generous gift from Prof. A. Kipar, University of
Liverpool, Great Britain), FPV (kindly provided by Prof.
U. Truyen, University of Leipzig, Germany), FHV ZH5-
04 strain and FCV F9 strain (kindly provided by Veteri-
naria AG, Zurich, Switzerland) were titrated on both
CrFK and fcwf-4 cells. Viral stock dilutions inducing
95% cytopathic effect (CPE) after 24 h (72 h for FCoV
and FPV) were selected for inhibition experiments in
order to ensure proper measurement of inhibitory
effects. Monolayers of CrFK and fcwf-4 cells in 96-well
plates were incubated for 24 h with 100 μL of the super-
natants produced with PBMCs from cats of groups 1, 2
and 3. With the exception of assays carried out with
FPV, viral inhibition experiments were conducted simul-
taneously and with supernatants thawed an equal num-
ber of times. The treated cells were then inoculated with
virus (VSV, FCV, FHV, FCoV) or trypsinized with 0.05%
trypsin-EDTA (Gibco®, Invitrogen) and allowed to settle
in viral suspension (FPV), and inhibition assays were
carried out after 24 h (72 h for FCoV and FPV) accord-
ing to the procedure described previously [62]. Briefly,
supernatants were discarded and cell debris was
removed from the wells by 3 cycles of washing with
Hank’s balanced salt solution (HBSS) (Gibco, Invitrogen)
and shaking on an orbital shaker for 15 s. Remaining
cells were fixed with 5% formalin and stained with a
crystal violet solution. For spectrophotometric mea-
surements, 100% methanol was added to the dried
out wells and absorbance was read at 595 nm on
a SpectraMax Plus 384 microtiter plate reader
(Molecular Devices, Bucher Biotec AG, Basel,
Switzerland). Viral inhibition rates were calculated
with the following formula:
Mean optical density ODð Þ values of duplicate wells treated with Supernatant
Mean OD values of quadruplicate wells treated with medium alone
FeLV-A Glasgow-1 strain (a generous gift from Prof.
M. Hosie and O. Jarret, University of Glasgow, Great
Britain) was titrated on FEA cells, and the lowest stock
dilution leading to productive infection of the cells after
48 h was used for inhibition assays. Experiments were
carried out in 96-well plates and cells were treated with
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100 μL of supernatants or relevant controls immediately
prior to inoculation. Every second day thereafter, 50 μL
culture medium was replaced by the same volume of
fresh supernatant. At appropriate time points, cells and
supernatants were harvested and total nucleic acid was
extracted from both the cells and supernatants using the
MagNA Pure LC DNA Isolation Kit I and MagNA Pure
LC Instrument (Roche Diagnostics). Viral replication in
supernatants and proviral loads in cells were measured
by real-time RT-PCR and real-time PCR respectively,
with assays previously described [63]. The time course
experiments were conducted with supernatants derived
from PBMCs of three cats and the measurements on day
8 post inoculation were carried out with material derived
from two additional cats. In order to facilitate interpret-
ation of the figures illustrating measurements of viral
RNA loads, 45 cycles-cycle threshold (Ct) values were
calculated and means of duplicate wells are depicted.
In vivo experiment
Cats c05 and c06 were administered ODN 2216 once sub-
cutaneously at a dose of 0.2 mg/kg body weight while cats
c07 and c08 received endotoxin-free PBS as control. The
treatments were distributed in equal portions bilaterally in
axillary and inguinal regions. Heparinized blood was col-
lected at time points 0 h (just before injection of the treat-
ment), 8 h, 24 h, 48 h, 96 h and 192 h. The cats were
clinically examined and body temperature was measured
at each time point. Whole blood samples were used in
part for the assessment of hematological paramaters with
the Sysmex XT 2000iV (Sysmex, Norderstedt, Germany)
as previously described [57]. The rest of the blood was
mixed with mRNA lysis buffer (Roche Diagnostics) imme-
diately upon blood collection and processed as recom-
mended by the manufacturer. Plasma was obtained by
centrifugation of whole blood samples for 10 min at
1500× g and conserved at −80°C until use for in vitro
experiments. Mx mRNA expression was measured by
qPCR and normalized to the expression of two feline
housekeeping genes as described above. The expression
factors depicted in the figures represent the ratio of
mRNA levels from a specific time point to mRNA levels
from time point 0 h. For viral inhibition assays, the plasma
collected from each cat at each time point was incubated
for 24 h with fcwf-4 cells prior to their inoculation with
FCV. The assays were carried out as described above and
viral inhibition factors were calculated as follows:
Mean optical density ODð Þ values of duplicate wells treated with plasma from timepoint 0h
Mean OD values of duplicate wells treated with plasma from timepoint Xh
Statistical analysis
All statistical analyzes were performed using GraphPad
Prism for Windows, version 3.0 (GraphPad Software,
San Diego California USA). Due to the limited number
of cats integrated in the study, we refrained from using a
parametric approach in the statistical tests. As such tests
require a larger sample size than n= 4, it was not pos-
sible to calculate p-values for the induction in expression
of each gene shown in Figure 2. Differences between
treatment groups in proliferation of PBMCs were ana-
lyzed with a Mann–Whitney test and expression of co-
stimulatory molecules on the surface of these cells were
analyzed with a Wilcoxon signed rank test, where values
for each cat were paired. Relative Mx mRNA expression,
OD values from viral inhibition assays, ratios for FeLV
provirus and Ct values for FeLV viral RNA loads were
analyzed with a Wilcoxon signed rank test with pairing
of values for each cat when treatment with different
supernatants were compared, or a Mann–Whitney test
when incubation with supernatant was opposed to treat-
ment with medium alone or rfeIFNα. Normalized and
relative TLR9 mRNA expression ratios between different
animal age groups were also compared with a Mann–
Whitney test. Longitudinal effects on FeLV viral and
proviral loads were compared with each other using a
Mann–Whitney test carried out with Area Under the
Curve (AUC) values. Correlations were assessed using
the Spearman test. p-values < 0.05 were considered sta-
tistically significant.
Results
Prototype CpG-A, ODN 2216, induce proliferation of
primary feline immune cells and enhance their expression
of costimulatory surface molecules
Proliferation of PBMCs in response to treatment with
CpG ODN gives strong indications about the biological
activity of the stimulatory molecule and has been used
to screen ODN in many species [25]. In relation to this,
the potential of CpG-A to induce proliferation of feline
PBMCs were assessed by measurement of 3H-thymidine
incorporation after stimulation. Although considerable
variability was observed between individuals, a 2-fold in-
crease in proliferation was observed after stimulation
with ODN 2216 when compared to stimulation with in-
active control ODN 2243 (p= 0.0281, Figure 1A). The
cells of three cats (c08, c09, c12) could be stimulated to
particularly high proliferative rates by ODN 2216 (values
above the mean of eight cats illustrated in Figure 1A) in
the following order: c08 > c12 > c09.
Another characteristic feature of stimulatory ODN is
their ability to enhance interactions between various im-
mune cell populations by upregulation of cell surface
costimulatory molecules. With the objective to test
whether ODN 2216 could exert such properties in feline
immune cells, the expression of B7.1 and MHCII was
measured by flow cytometry in stimulated PBMCs of the
same eight cats as above. The expression of both co-
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stimulatory molecules was evaluated in gates defined to
contain a PBMC population, a lymphocyte population
and a non-lymphocyte population of cells. The observed
effects varied considerably between the cells of individ-
ual cats, ranging from no alterations to an increase of
400% stained cells in some cellular subpopulations after
ODN 2216 stimulation. Also, in some animals, stimula-
tion with the control ODN 2243 indicated similar stain-
ing patterns as PBS, whereas in other cats the induction
of effects comparable to those of ODN 2216 could be
observed. The response of cells originating from a par-
ticular cat to stimulation with ODN 2243 did not how-
ever correlate with the influence of ODN 2216 on the
expression of either surface molecule on these same
cells. Overall, an increased expression of both B7.1 and
MHCII was measured in gated PBMCs upon a 24 h
stimulation with ODN 2216 when overlaid with the ex-
pression of these molecules after ODN 2243 or PBS
stimulation (Figure 1B and C). Considering all eight cats,
lymphocytic cells expressed significantly higher levels of
B7.1 and MHCII when exposed to ODN 2216 than after
treatment with PBS (p= 0.0195 and p=0.039 respectively,
Figure 1D and F). Feline MHCII expression on lympho-
cytes also seemed to be affected by ODN 2216 and ODN
2243 in a similar manner (Figure 1F). For non-
lymphocytic cells, ODN 2216 more specifically affected
the expression of B7.1 molecules, inducing significant
upregulation of surface levels of this molecule when com-
pared to stimulation with ODN 2243 (p=0.0391) and
PBS (p=0.0039) for 24 h (Figure 1E). In contrast, the ex-
pression of MHCII was not significantly altered in cells
gated as non-lymphocytes at this time point after stimula-
tion (Figure 1G). Finally, the cells of the three cats (c08,
c09 and c12) that exhibited the highest proliferation rates
in response to ODN 2216 (Figure 1A) also indicated the
strongest increase in expression of both cell surface mole-
cules in all cellular subpopulations tested.
ODN 2216 influence type I IFN and proinflammatory gene
expression in primary feline immune cells
Through interaction with the TLR9, CpG-A typically in-
duce expression of both type I IFN and proinflammatory
cytokines in stimulated cells [12]. In order to understand
whether ODN 2216 exert similar effects in the cat, trea-
ted cultures of feline PBMCs, FEA, CrFK and fcwf-4
cells were systematically screened for increased mRNA
expression of IFNα and IL-6 following stimulation. Al-
though all tested immortalized feline cell lines expressed
TLR9 mRNA (data not shown), they failed to respond to
stimulation with ODN 2216 (Figure 3A and B and data
not shown). However, this molecule exhibited potent
immunomodulatory properties in feline PBMCs: when
measured 24 h post stimulation, a concentration of only
1 μg/mL ODN 2216 was sufficient to enhance transcrip-
tion of IFNα by 40-fold, and a maximum induction of
this gene was observed when 4 μg/mL ODN were used
(Figure 3C). Although affected in a similar pattern, the
mRNA expression of the proinflammatory cytokine IL-6
remained comparatively low at all concentrations tested
(Figure 3D). In experiments foreseen to determine gene
expression kinetics in feline cells after stimulation with
the ODN 2216 molecule, an influence on IFNα tran-
scription could be measured as early as 3 h after treat-
ment of PBMCs, whereas increased levels of IL-6 mRNA
were observed only as of 6 h post stimulation (Figure 3E
and F). Notably, the highest induction of both genes was
measured 24 h after addition of ODN 2216 to the cul-
tures, with transcription increasing by 9000-fold and 39-
fold at this time point for IFNα and IL-6 respectively
(Figure 3E and F). The observed effects were specifically
conferred by the CpG motifs comprised in the 2216
ODN, since specific control ODN 2243 only induced
slight elevations in the expression of the genes tested
(Figure 3C-F). Importantly, trypan blue exclusion experi-
ments indicated no evidence of cellular toxicity after
treatment neither with ODN 2216 nor with ODN 2243
at all concentrations tested (data not shown).
ODN 2216 broadly influence the gene expression profile
in primary feline immune cells of adult cats
In an effort to assess both the breadth of the effects con-
ferred by treatment with a CpG-A and possible variabil-
ity in the responses obtained in individual cats, the
mRNA expression of ten genes relevant to early immune
responses was measured in ODN 2216 stimulated
PBMCs of fourteen cats divided in four different age
groups (group 1: 10 weeks (n= 4), group 2: 1.5 years
(n= 4), group 3: 7 years (n= 4), group 4: 14 years
(n= 2)). Only slight individual variability in gene induc-
tion was observed after 24 h stimulation of immune cells
from adult cats ranging between 1.5 and 14 years of age
(Figure 2B-D). Overall, the mRNA expression profile
(See figure on previous page.)
Figure 2 ODN 2216 induces an antiviral gene expression profile in PBMCs of adult cats. (A-D) mRNA expression factors of the indicated
genes were measured in PBMCs isolated from fourteen cats belonging to the indicated age groups and stimulated with ODN 2216 for 24 h. (E)
mRNA expression factors of the indicated IFNα subtype genes were measured in PBMCs isolated from four adult cats (group 2) and stimulated
with ODN 2216 for 24 h. (F) mRNA levels of TLR9 were measured by real-time qPCR in unstimulated PBMCs of all four groups of cats and
normalized to the expression of a feline housekeeping gene (GAPDH). (G) Relative TLR9 mRNA expression factors were measured in ODN 2216
stimulated PBMCs from cats of all four groups. *p< 0.05, Perf = perforin, GranB= granzyme B.
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measured in stimulated PBMCs of these cats corrobo-
rated their induction of strong antiviral immune
responses. The expression of type I IFN mRNA, includ-
ing IFNα, IFNβ and IFNω was substantially increased in
the immune cells subjected to ODN 2216 stimulation
from every adult cat, with minimal inductions of 490, 60
and 1600-fold respectively observed in the older animals
of group 4 (Figure 2D). Moreover, all individual IFNα
subtypes tested were induced at similar levels in the cells
of four adult cats from group 2 (Figure 2E). Increased
levels of proinflammatory cytokine mRNA were also
measured in most individuals of groups 2–4, with IL-6
more systematically increased than TNFα. The cells
from these cats indicated a typical Th1 orientation after
stimulation, with enhanced transcription of IL-12 in 9/
10 and IFNγ in 6/10 animals, together with absent or
only low induction of IL-4. Stimulation of PBMCs with
ODN 2216 also created an optimal environment for NK
cell activity, as indicated by the increases in mRNA ex-
pression of the NK cell stimulator IL-15 by up to 20-fold
and of the NK cell effector Granzyme B by up to 7-fold.
The cells of those cats (c08, c09, c12) that had most
Figure 3 ODN 2216 influence IFNα and IL-6 expression in primary feline immune cells. mRNA expression factors of IFNα and IL-6 were
measured in (A, B) fcwf-4 cells stimulated with ODN 2216 and (C-F) feline PBMCs from one cat belonging to group 2 stimulated with either ODN
2216 or control ODN 2243. The transcription of both genes was assessed either 24 h after treatment of the cells with increasing concentrations of
ODN (A, C, D), or over time after a single stimulation with 4 μg/mL ODN (B, E, F). Experiments C-F were repeated for 4 adult cats and
representative results are shown.
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effectively proliferated (Figure 1A) and/or exhibited
the strongest expression of co-stimulatory molecules
(Figure 1B-E) following ODN 2216 stimulation also
consistently expressed the highest mRNA levels of
IFNα, IFNω, IL-6, Il-12, IL-15 and Granzyme B. PBMCs
of cat c08 (group 2, Figure 1B) were also by far most
responsive to stimulation with ODN 2216. When cells
from kittens of group 1 were stimulated, higher individ-
ual variability was observed than in adult animals
(Figure 2A). The PBMCs of only 2 out of 4 cats from
this group could be stimulated with ODN 2216 to in-
crease mRNA expression of the tested genes. In both
individuals, not only the mRNA expression of type I
IFN genes was enhanced at much lower levels than
observed in adult cats but the overall immune re-
sponse favored a Th2 direction, characterized by upre-
gulated IL-4 and downregulated IL-12 mRNA levels
(Figure 2A).
In order to determine whether a discrepancy in
expression of TLR9 between the PBMCs of adult
animals and kittens could play a role in these
observations, mRNA levels of this gene were measured
in immune cells of each cat. Although basal TLR9
expression was similar in the PBMCs of the cats of
all age groups (Figure 2F), ODN 2216 stimulation
increased TLR9 transcription in the cells of kittens, but
decreased transcription of this gene in the cells of adult
cats so that differences in the mRNA levels of this recep-
tor were significantly higher in young cats (group 1)
than in adult cats of groups 2 and 3 (p= 0.0286)
(Figure 2G).
ODN 2216 induce the production of soluble molecules
that activate intracellular antiviral mechanisms in feline
target cells
Protective properties of type I IFN against viruses origin-
ate from their ability to trigger the production of potent
antiviral proteins in nearby cells. The expression of one
of these antiviral proteins, the Mx GTPase, is known to
be directly stimulated by type I IFN and can be used as
marker for the induction of intracellular antiviral
mechanisms by these cytokines in cats as well as in
other species [19,64]. Thus, as detection of feline type I
IFN on a protein level is rendered difficult by the un-
availability of antibodies specifically recognizing these
proteins, mRNA levels of Mx were measured in feline
PBMCs after stimulation with ODN 2216, as indication
for production of type I IFN. Transcription of Mx was
significantly enhanced and remained proportional to
mRNA expression of type I IFN in stimulated PBMCs of
individual cats (Figure 4A). Moreover, peak levels of Mx
mRNA were measured 24 h after stimulation of the
cells, indicating the presence of optimal effects of the
type I IFN present in the cell culture medium at this
time point (Figure 4B). In order to further determine
the potential of the type I IFN liberated by ODN 2216
stimulated PBMCs to induce intracellular antiviral
mechanisms in non-immune target cells, cell-free super-
natants of PBMCs derived from the blood of individual
adult cats and stimulated in vitro for 24 h with ODN
2216, ODN 2243 or endotoxin-free PBS (Sup 2216, Sup
2243 and Sup Neg respectively), were incubated with
CrFK and fcwf-4 cells. Mx gene transcription was signifi-
cantly enhanced in cells treated with Sup 2216 compared
to Sup 2243 (p= 0.0078) and Sup Neg (p= 0.0078), at
levels comparable to those achieved by stimulation of
the cells with 100U recombinant feline IFNα (rfeIFNα)
(Figure 4C and data not shown). The Sup 2216 derived
from cells of individual animals (c08, c09, c12) that had
shown particularly strong responses to ODN 2216 in
previous experiments also induced the highest Mx
mRNA expression in both cell lines tested. Although
treatment with Sup 2243 systematically increased Mx
transcription in target cells, protein levels remained low
(Figure 4D and data not shown). Furthermore, peak in-
duction of Mx transcription was observed in both cell
lines already within 6 hours of incubation with Sup 2216
(Figure 4E and data not shown), while protein levels
achieved maximum levels within 24 h post stimulation
and remained stable thereafter for at least another 24–
48 h (Figure 4F and data not shown).
ODN 2216 inhibit replication of common feline viruses
in vitro
Felids are frequently affected by four viruses of different
families: the feline herpesvirus (FHV), calicivirus (FCV),
parvovirus (FPV) and coronavirus (FCoV). Although
these viruses cannot productively infect purified PBMCs
in vitro, they share the ability to induce cytopathic
effects (CPE) in CrFK and fcwf-4 cells. These feline cell
lines, however, do not alter their mRNA levels of genes
selected as markers for innate immunity upon direct
treatment with ODN 2216 (Figure 3A and B and data
not shown), preventing from assessing the potential of
this molecule to inhibit viral replication directly in these
cells. Thus, CrFK and fcwf-4 cells were incubated, prior
to their inoculation, with the cell-free supernatants of
PBMCs mentioned above: Sup 2216, Sup 2243 and Sup
Neg. To this aim, supernatants derived from PBMCs
treated for 24 h were selected, as Sup 2216 produced by
the cells of several adult cats were estimated to contain
optimal type I IFN amounts at this time point, according
to the induction of Mx transcription measured directly
in these immune cells (Figure 4A and 4B). CrFK and
fcwf-4 target cells were then incubated with the superna-
tants for 24 h before inoculation, as this time span had
indicated highest induction of antiviral mechanisms
(Figure 4F). The antiviral effects of the supernatants
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were initially tested on vesicular stomatitis virus (VSV)
as control, as this virus is widely recognized for both its
potential to induce CPE in cell lines of multiple species
and for its particularly high sensitivity to the effects of
type I IFN [65, 66]. When the Sup 2216 derived from
the PBMCs of eight adult cats that had broadly
responded to in vitro ODN 2216 stimulation (Figure 2B
and C, groups 2 and 3) were incubated with fcwf-4 cells
prior to their inoculation, significant inhibition of VSV
replication was observed (p= 0.0039) (Figure 5A). The
replication of this virus was also to some degree
repressed by Sup 2243 (p= 0.0078), an observation
Figure 4 ODN 2216 induces an antiviral state both in stimulated PBMCs directly and in target cells incubated with supernatants from
stimulated PBMCs. (A) mRNA expression factors of the indicated genes were measured in PBMCs of the individual cats (c01-c14) from four
different age groups after stimulation with ODN 2216 for 24 h. (B) Mx mRNA expression factors were assessed at the indicated time points in
PBMCs of one cat after a single stimulation with either ODN 2216 or ODN 2243. (C) Mx mRNA expression factors were measured in fcwf-4 cells
incubated for 24 h with supernatants (Sup 2216, Sup 2243, Sup Neg) derived from PBMCs of eight adult cats (groups 2 and 3) or 100U
recombinant feline IFNα (rfeIFNα). (D) Mx protein was detected by Western blot in fcwf-4 cells incubated with the indicated supernatants derived
from PBMCs of one cat belonging to group 2 or with 100U recombinant feline IFNα (rfeIFNα) for 24 h. (E) Mx mRNA expression factors were
measured in fcwf-4 cells at the indicated time points after a single stimulation with Sup 2216, Sup 2243 and Sup Neg respectively. (F) Mx protein
was detected by Western blot in fcwf-4 cells at indicated time points after stimulation with Sup 2216 derived from PBMCs of the same cat (right
panel). **p< 0.01. rfeIFNα= recombinant feline IFNα.
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reminiscent of the slight induction of Mx in target cells
incubated with these supernatants (Figure 4C and D). In
turn, the propagation of FCV, FCoV, FHV and FPV on
fcwf-4 cells was also significantly suppressed by the Sup
2216 when compared to Sup 2243 (p= 0.0039,
p= 0.0039, p= 0.0078 and p= 0.0039 respectively) and
Sup Neg (p= 0.0039), however with expected lower sen-
sitivity than VSV (Figure 5B-E and Table 1). Both Sup
2243 and Sup Neg failed to inhibit replication of this
heterogeneous group of feline viruses, underlining the
essential role of the 2216 molecule in conferring the
observed effects. Importantly, cells stimulated with ODN
2216 directly did not indicate any resistance to viral rep-
lication, in concordance to their impaired response to
this molecule already measured on a genetic level
(Figure 3A and B and data not shown). With respect to
the younger cats, the Sup 2216 of those 2 kittens whose
cells responded to ODN 2216 stimulation (Figure 2A,
group 1) could also inhibit both VSV and FCV on fcwf-4
cells, while the supernatants derived from the PBMCs of
the other 2 kittens indicated no inhibition potential on
these viruses (Figure 5K and L). Altogether, the viral
suppression potential of Sup 2216 from all the cats could
be compared to that conferred by treatment of the cells
with 10 to 100U rfeIFNα, a quantity determined in titra-
tion experiments of rfeIFNα conducted together with
the viral inhibition assays (data not shown).
The differential inhibition of the viruses tested by the
same supernatants is reflected by the distinct viral inhib-
ition ratios observed (Figure 5B-E and Table 1).
Sensitivity of each virus to rfeIFNα correlated with sensi-
tivity to the Sup 2216 and induction of Mx in target cells
by the supernatants highly correlated with the inhibition
of all viruses (Figure 5F-I). Finally, Sup 2216 derived
from PBMCs of cats c08, whose cells had indicated
strong responsiveness to stimulation with ODN 2216 in
previous experiments, most efficiently inhibited the rep-
lication of all viruses.
Similar results were notably obtained when the super-
natants of PBMCs derived from all cats were incubated
with CrFK cells prior to their inoculation with all the
above-mentioned viruses (data not shown). This cell line
has previously indicated less sensitivity to the antiviral
effects of type I IFN [66] and generally 10-fold higher
amounts of rfeIFNα were found in titration experiments
to be required for the inhibition of all five viruses. Con-
cordantly, average fold viral inhibition in CrFK cells by
the Sup 2216 was approximately half that observed in
fcwf-4 cells.
ODN 2216 inhibits replication of a retrovirus in vitro
The life cycle of retroviruses is characterized by the re-
verse transcription of their genomic RNA into DNA and
subsequent integration of this viral DNA as provirus into
the genome of the host, causing permanent infection
most often accompanied by persistent virus production
by infected cells. The feline leukemia virus (FeLV), a
gammaretrovirus that can be propagated on FEA cells
in vitro, affects domestic cats worldwide. As viral repli-
cation in chronically infected cats can be lowered by
treatment with IFNα [67], the potential of Sup 2216 pro-
duced by the PBMCs of five adult cats (c06 and c08
from group 2; c09, c10, c12 from group 3) to inhibit pro-
ductive infection of FEA cells was analyzed. In initial
experiments, this cell line exhibited similar responses as
fcwf-4 and CrFK cells to both direct treatment with
ODN 2216 and incubation with the different superna-
tants (Figure 3A, 4C and D and data not shown). Com-
pared to incubation with medium alone, treatment of
FEA cells with Sup 2216 for 24 h prior to inoculation
with FeLV followed by repetitive treatments of the cells
with this supernatant every 2 days thereafter significantly
reduced viral RNA (p < 0.05) and DNA (p < 0.05)
(See figure on previous page.)
Figure 5 Supernatants derived from ODN 2216 stimulated PBMCs inhibit viral replication in target cells. (A-E) fcwf-4 cells were incubated
for 24 h with the indicated supernatants derived from PBMCs of eight adult cats (groups 2 and 3) or medium only as control before inoculation
with the indicated viruses. Each dot represents mean optical density (OD) values from spectrophotometric readings of viral inhibition assays
conducted on duplicate wells treated with supernatants from an individual cat. (F-J) Correlation of individual inhibition ratios of each virus with
Mx mRNA expression induced in fcwf-4 cells incubated with supernatants of ODN 2216 stimulated PBMCs from the eight cats of groups 2 and 3.
Note the different scale on the x-axis for each graph indicating the differences in the inhibitory effects of these supernatants on the different
viruses. (K, L) fcwf-4 cells were incubated for 24 h with the indicated supernatants derived from PBMCs of 4 kittens (group 1) or medium only as
control before inoculation with VSV or FCV. Each dot represents mean OD values from spectrophotometric readings of viral inhibition assays
conducted on duplicate wells treated with supernatants from one cat. **p< 0.01. VSV = vesicular stomatitis virus, FCV= feline calicivirus,
FPV= feline parvovirus, FCoV= feline coronavirus, FHV= feline herpes virus.
Table 1 Means of viral inhibition rates measured in fcwf-4
cells after treatment with supernatants derived from
stimulated PBMCs of 8 adult cats
VSV FCV FCoV FHV FPV
Sup 2216 23.49 12.94 8.85 6.18 3.74
Sup 2243 8.74 3.53 2.68 1.65 1.20
Sup Neg 4.26 2.65 2.25 1.29 1.52
Depicted are mean viral inhibition rates for 8 cats. Viral inhibition rates for
each cat were calculated with the following formula:
Mean optical density ODð Þ values of duplicate wells treated with Supernatant
Mean OD values of quadruplicate wells treated with medium alone .
Abbreviations: VSV Vesicular Stomatitis Virus, FCV Feline Calicivirus, FCoV Feline
Coronavirus, FHV Feline Herpesvirus, FPV Feline Parvovirus.
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measured in the cell culture supernatants and cells re-
spectively as of 4 days post inoculation (Figure 6A and
B). The antiviral potential of the supernatants from the
individual cats was very similar; however the best results
were conferred by the Sup 2216 derived from cells of
c08 (depicted in Figure 6A and B).The kinetic curve of
viral RNA loads in cultures of cells treated with Sup
2216 of this cat was similar to those obtained in cells
treated with 50U rfeIFNα (data not shown). Also, treat-
ment of the cells with ODN 2216 directly affected nei-
ther viral RNA nor viral DNA loads measured in the
supernatants and the cells respectively (data not shown).
Mx mRNA expression was 80-fold higher in the Sup
2216 treated cells than in all controls 8 days post inocu-
lation, indicating the ability of these supernatants to sus-
tain antiviral mechanisms when applied to the cells
repeatedly (Figure 6C). Furthermore at this time point,
the Sup 2216 treated cells exhibited significantly lower
viral DNA loads (p= 0.0313) and produced significantly
less virus (p= 0.0313) than cells treated with Sup 2243,
Sup Neg or medium alone (Figure 6D and E). The extent
of Mx transcription conferred by the Sup 2216 of the
cats strongly correlated with lower provirus (p= 0.0053)
and virus (p= 0.0012) loads measured in the FEA cells
and supernatants respectively on day 8 post inoculation
(p= 0.0053). Also, the highest Mx mRNA levels in target
cells were conferred by Sup 2216 of cat c08 and reflected
by the lowest viral and proviral loads measured at this
time point in our experiments.
ODN 2216 induces an antiviral state in the domestic
cat in vivo
In a final step, the induction of antiviral responses by
ODN 2216 was measured in vivo and characterized
using ex vivo assays. The molecule was administered
once subcutaneously to two cats (c07 and c08), while
two other cats (c05 and c06) received endotoxin-free
PBS as a negative control. The injections were well
tolerated by all cats: no rise in body temperature, no
local reactions at the injection site and no other un-
desired side effects were noted. Absolute monocyte
counts increased 1.5 to 2-fold in the first 12 h in cats
that had received ODN 2216 (data not shown). No
other treatment-specific alterations were noted in
hematological values throughout the experiment. Mx
expression was measured in blood at early time points
after injection as marker for the induction of antiviral
immune processes. mRNA levels of Mx increased by
8.8 and 3.8-fold within 24 h in both treated cats and
decreased gradually thereafter until 192 h post treat-
ment (Figure 7A). In accordance with observations
from in vitro experiments, cat c08 exhibited a stronger
response to ODN 2216 than cat c07. No increase in
Mx expression was observed in the blood of the con-
trol cats (c05 and c06). In a further experiment, plasma
was collected from all four cats at regular intervals post
injection and was utilized in an in vitro inhibition
assay. The plasma obtained from both treated cats 24
and 48 h after administration of the molecule was able
to inhibit replication of FCV in vitro (Figure 7B). In
contrast, plasma from untreated cats seemed to slightly
enhance the susceptibility of target cells to FCV
inoculation.
Discussion
In the present study, we conducted both in vitro and
in vivo experiments that characterize immunomodula-
tory and antiviral effects of a CpG-A molecule in the
domestic cat. We show that ODN 2216, the first
described CpG-A [12], can upregulate the expression of
a series of genes in feline immune cells that play im-
portant roles in early responses to viruses. Soluble
molecules produced by feline PBMCs upon ODN 2216
stimulation significantly increased resistance of various
feline target cell lines to propagation of viruses from
five different families, namely FCV, FPV, FHV, FCoV
and FeLV. The observed repression of viral replication
highly correlated with the mRNA expression of type I
IFN genes in stimulated PBMCs as well as the induc-
tion, prior to inoculation, of antiviral mechanisms in
the target cells. Furthermore, a single administration of
ODN 2216 significantly increased the expression of Mx
in the blood of treated cats. Plasma from these animals
could also inhibit replication of FCV in vitro. Our data
underline the prophylactic potential of ODN 2216 in
an outbred species as a stand-alone agent and against a
(See figure on previous page.)
Figure 6 Supernatants derived from ODN 2216-stimulated PBMCs decrease retroviral DNA and RNA loads in target cells. (A) FEA cells
were incubated for 24 h with the respective supernatants or medium alone, before inoculation with the feline leukaemia virus (FeLV), as well as
every 2 days thereafter. Viral RNA loads were measured at the indicated time points by real time RT-PCR and 45-Ct values are depicted. (B) FeLV
DNA loads in the cells were measured at the indicated time points and Ct values were normalized to detection of a housekeeping gene (GAPDH).
Mean values from duplicate experiments carried out simultaneously with the supernatants derived from PBMCs of a selected cat (belonging to
group 2) and with medium alone are shown as an example. Results for (A) and (B) are indicative of those obtained with supernatants from PBMCs
of two additional adult cats (from group 3). Stars represent statistical differences in area under the curve (AUC) measurements between the curves
of all three cats obtained in cells incubated with Sup 2216 and each of the other treatments. Mx mRNA expression factors (C), viral loads (45-Ct
values depicted) (D) and proviral loads (E) were measured in the FEA cells of five cats (two from group 2 and three from group 3) on day 8 post
inoculation. Each dot represents the mean of duplicate measurements for an individual cat. *p< 0.05, **p< 0.01.
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large range of viral pathogens simultaneously. Cats may
highly benefit from such a molecule when placed in
environments with strong infectious pressure such as
catteries, shelters or pet shows.
Cells of the feline immune system were strongly influ-
enced when cultured in the presence of ODN 2216. First,
feline PBMCs significantly proliferated in presence of
ODN 2216, indicating a direct and /or indirect stimula-
tion of one or more immune cell subpopulations by this
molecule. Although in contrast to other classes of ODN
CpG-A does not generally induce lymphocyte prolifera-
tion in mice [12], similar effects have previously been
observed in ovine cells, where higher concentrations of
CpG-A could induce minimal levels of proliferation [68].
Additionally, ODN 2216 increased the expression of cell
surface co-stimulatory molecules in PBMCs, reinforcing
possible interactions between various immune cell popu-
lations in subsequent specific responses. While B7.1
molecules were upregulated on both lymphocytic and
non-lymphocytic cells after ODN 2216 stimulation,
MHCII expression could only be increased on lympho-
cytic cells. This observation may be linked to the time
point of our measurements, or to the necessity of trans-
port to the cell surface of MHCII molecules coupled with
antigen for presentation to other immune cells. Finally,
the transcription of a series of markers of innate immune
responses was considerably influenced in feline PBMCs
by stimulation with ODN 2216. The most astonishing
effects of this molecule thereby remain the potent induc-
tion of IFNα and IFNω, with mRNA expression of these
genes increased by up to 12 000 and 35 000-fold respect-
ively in PBMCs of certain animals. In line with observa-
tions published recently, the induction of IFNγ by this
CpG ODN remained moderate [34]; nevertheless, the
measurements carried out 24 h after stimulation of puri-
fied feline cells support induction of Th1-oriented im-
mune responses and enhanced NK cell activity, both
highly desired in the contexts of viral infection.
Variability in the immunomodulatory and antiviral
effects of ODN 2216 on feline cells was mainly related
to the age of the cats. Among middle-aged adult cats,
consistency in the stimulatory potential of this molecule
was reflected through the highly similar patterns in gene
expression profiles induced in immune cells after stimu-
lation, as well as through the moderate deviations in
those experiments aiming to characterize the immuno-
modulatory properties of ODN 2216 (Figure 1). The
cells of several animals however, in particular cat c08,
but also c09 and c12, indicated particularly strong re-
sponsiveness to stimulation throughout the study. Such
observations are most likely linked to the genetic vari-
ability of individuals of an outbred species, as inherited
factors are known to play an important role in the mag-
nitude of innate immune responses [69]. With respect to
this observation, it should be noted that the SPF origin
and maintenance in a barrier facility of the animals
Figure 7 Subcutaneous injection of ODN 2216 induces a systemic antiviral state in vivo. (A) The cats received an injection of either
200 μg/kg ODN 2216 (cats 1 and 2) or endotoxin-free PBS (cats 3 and 4). Mx mRNA expression was measured by qPCR in whole blood. Depicted
values represent the ratio of mRNA levels for a given cat (c05-c08) at the indicated time point to mRNA levels for the same cat at time point 0 h.
(B) fcwf-4 cells were incubated for 24 h in duplicates with plasma collected from the cats 1 to 4 at the indicated time points post injection, and
inoculated with the FCV. Indicated are viral inhibition factors calculated as described in the material and methods section. (C) Mx mRNA
expression factors measured in the blood of all four cats at time points 8 h-192 h were correlated with the inhibition of FCV induced in vitro by
the corresponding plasma samples.
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included in this study may slightly lower the variability
in strength and breadth of innate immune responses,
and studies with cells obtained from field cats would
give further information on divergence in response to
stimulation of the innate immune cells of individual ani-
mals. The immune cells of cats of 14 years of age
seemed to respond slightly less well to ODN 2216 than
those of younger adult animals, while PBMCs of kittens
indicated much more reticence to stimulation, with ei-
ther limited or absent upregulation of both type I IFN
and other genes measured after incubation with ODN
2216. Stimulated PBMCs from this group of young
animals moreover indicated a tendency to develop an
immunologic environment with a Th2 orientation, in-
cluding higher production of IL-4 and impaired induc-
tion of IL-12 compared to cells from adult cats.
Although the kittens included in this study were
already of 10 weeks of age, these observations strongly
corroborate the immature IFN system of neonatal mice
[70], the impaired immune cell activation via TLR9 in
human neonatal mononuclear cells [71,72] and the bias
towards Th2 rather than Th1 responses in human
fetuses and neonates [73,74]. Furthermore, concor-
dantly to findings in human neonatal blood [75,76],
basal TLR9 transcription in kittens indicated levels
similar to those of adults. However, ODN 2216 stimu-
lation increased mRNA expression of this gene only in
the young animals (Figure 2C). These results open new
perspectives on possible explanations for the qualitative
discrepancy between innate immune responses in new-
borns and adults. The availability of specific antibodies
to feline TLR9 would greatly support further investiga-
tions in this direction.
The experiments conducted both in vitro and in vivo
in this study underline the feasibility of utilizing Mx as a
marker for induction of resistance to viral infections in
the domestic cat. Admittedly, both the supernatants of
PBMCs stimulated with CpG-A and serum of treated
cats contain a mixture of molecules that could play a
role in the observed antiviral effects. However, the viral
inhibition in our in vitro assays was similar to that
obtained after treatment of the cells with rfeIFNα and
highly correlated with the induction of Mx transcription
in the cell lines incubated with the supernatants. After
ODN 2216 injection in vivo, Mx expression in plasma
also strongly correlated with its antiviral potential. It is
however important to note that Mx mRNA and protein
cannot be mechanistically linked to inhibition of the
viruses tested. Although the expression of other antiviral
molecules such as 2'5'oligoadenylate synthetase (OAS)
and the RNA-dependent protein kinase (PKR) was not
measured, their induction has been reported following
CpG ODN stimulation of PBMCs in other species
[77,78] and differential interplay between several effector
mechanisms most likely leads to the inhibition of indi-
vidual viruses.
In comparison to ODN of other groups, CpG-A have
been used in much fewer studies concerning innate anti-
viral responses. This is most likely the result of the more
time consuming and costly manufacturing process of
these molecules linked to the synthesis of the flanking
poly (G) strings necessary for optimal immune effects
[31]. Also, CpG-A exhibit only weak stimulation of B
cells, which produce antibodies that are valuable in later
antiviral responses. Stability of CpG-A in vivo has also
been questioned due to the only partial phosphorothio-
ate backbone of these molecules. This can be partially
compensated however, by the formation, through associ-
ation of their poly (G) stretches, of highly ordered G-
tetrad structures with enhanced stability [12]. Their
smaller content in synthetic backbones could moreover
help reduce possible long-term side effects [79,80]. Most
importantly, CpG-A remain the most potent inducers of
type I IFN, themselves the most biologically active anti-
viral molecules known to date [19]. With regard to this,
a recombinant feline type I IFN marketed in both Japan
(Intercat®) and Europe (Virbagen Omega®) has made its
way into therapeutic protocols for FCV, FHV, FeLV and
canine parvovirus infections [67,81-86] and has demon-
strated preventive capacities in a cattery developing an
outbreak of FPV [87]. However, when compared to dir-
ect initiation of antiviral mechanisms by a recombinant
IFNα protein, administration of CpG ODN holds the ad-
vantage of inducing the production of all type I IFN and
their subtypes, which have been shown to possess differ-
ential antiviral properties and kinetics [88]. Our data
demonstrate that five viral species belonging to the Cali-
civirus, Herpesvirus, Parvovirus, Coronavirus and Retro-
virus families were highly sensitive to the immunologic
effects of ODN 2216 in feline cells. Strength and breadth
of antiviral defense mechanisms induced in vivo by this
molecule have the potential to outweigh those observed
with recombinant IFN.
In frame with the results of our in vitro experiments,
the administration of ODN 2216 in vivo could promote
an antiviral state in the domestic cat in the absence of
adverse reactions. Just as stimulated PBMCs exhibited
high mRNA expression of type I IFN and only a mar-
ginal increase in mRNA levels of the proinflammatory
cytokines IL-6 and TNFα, treated cats showed signifi-
cantly increased Mx expression in their blood and lacked
flu-like symptoms generally linked with administration
of immunostimulatory molecules in vivo. Additionally,
although our in vivo studies included a limited number
of cats, the strength of responses to ODN 2216 stimula-
tion in vitro and in vivo for individual animals strongly
correlated, indicating that individual sensitivity to stimu-
lation most likely can be predicted with in vitro
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experiments. Our data further show that a single sub-
cutaneous injection of ODN 2216 sufficed to induce the
systemic presence of antiviral molecules for 24 to 36 h
in the plasma of treated cats; during this time, an in-
crease of Mx expression of at least 4-fold in the blood of
treated cats was indicative of significant inhibition of
viral replication in vitro. These observations support
possible resistance to viral infection by ODN 2216 for
several days, a phenomenon described already in mouse
models [89].
Altogether, this study underlines the strong potential
for ODN 2216 in the prevention of a large variety of
viral diseases. CpG-A molecules should thus not be left
aside when stimulating innate immunity for prophylactic
purposes. Future studies should aim at optimizing the
kinetics of these molecules in vivo, while addressing
safety, stability and manufacturing issues. Combinations
with adjuvants or other TLR agonists as well as opti-
mized administration protocols should support research
in this direction. Field studies with larger cohorts of ani-
mals will provide further insights on the utilization of
CpG-A molecules for the prevention of viral infections
in a clinical setting.
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